参考文献

1.Global Initiative for Chronic Obstructive Lung Disease(GOLD).Global Strategy for the Diagnosis，Management and Prevention of Chronic Obstructive Pulmonary Disease(2017 Report).2017.

2.中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版).中国医学前沿杂志(电子版)，2014.，6(2)：67-80.

3.Lim SS，Vos T，Flaxman AD，et al.A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010.Lancet，2012，380(9859)：2224-2260.

4.Vos T，Flaxman AD，Naghavi M，et al.Years lived with disability(YLDs)for 1160 sequelae of 289 diseases and injuries 1990-2010：a systematic analysis for the Global Burden of Disease Study 2010.Lancet，2012，380(9859)：2163-2196.

5.A llinson JP，Hardy R，Donaldson GC，et al.The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.Am J Respir Crit Care Med，2016，193(6)：662-672.

6.Lange P，Celli B，AgustíA，et al.Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.N Engl J Med，2015，373(2)：111-122.

7.Zhong N，Wang C，YaoW，et al.Prevalence of chronic obstructive pulmonary disease in China：a large，population-based survey.Am J Respir Crit Care Med，2007，176(8)：753-760.

8.包鹤龄，方利文，王临虹.1990—2014年中国40岁及以上人群慢性阻塞性肺疾病患病率Meta分析.中华流行病学杂志，2016，37(1)：119-124.

9.Mathers CD，Loncar D.Projections of global mortality and burden of disease from 2002 to 2030.PLoSMed，2006，3(11)：e442.

10.Halbert RJ，Natoli JL，Gano A，etal.Global burden of COPD：systematic review and meta-analysis.Eur Respir J，2006，28(3)：523-532.

11.Mannino DM，Buist AS.Global burden of COPD：risk factors，prevalence，and future trends.Lancet，2007，370(9589)：765-773.

12.Buist AS，Vollmer WM，McBurnie MA.Worldwide burden of COPD in high-and low-income countries.Part I.The burden of obstructive lung disease(BOLD)initiative.Int J Tuberc Lung Dis，2008，12(7)：703-708.

13.Lamprecht B，McBurnie MA，Vollmer WM，et al.COPD in never smokers：results from the population-based burden of obstructive lung disease study.Chest，2011，139(4)：752-763.

14.A l GM，Alhamad EH，A lorainy HS，et al.The prevalence of chronic obstructive pulmonary disease in Riyadh，Saudi Arabia：a BOLD study.Int JTuberc Lung Dis，2015，19(10)：1252-1257.

15.Denguezli M，Daldoul H，Harrabi I，et al.COPD in Nonsmokers：Reports from the Tunisian Population-Based Burden of Obstructive Lung Disease Study.PLoSOne，2016，11(3)：e0151981.

16.El RK，Nejjari C，BenJelloun MC，et al.Prevalence of chronic obstructive pulmonary disease in Fez，Morocco：results from the BOLD study.Int JTuberc Lung Dis，2016，20(1)：136-141.

17.Obaseki DO，Erhabor GE，Gnatiuc L，et al.Chronic Airflow Obstruction in a Black African Population：Results of BOLD Study，Ile-Ife，Nigeria.COPD，2016，13(1)：42-49.

18.Adeloye D，Chua S，Lee C，et al.Global and regional estimates of COPD prevalence：Systematic review and meta-analysis.J Glob Health，2015，5(2)：020415.

19.Lopez AD，Shibuya K，Rao C，et al.Chronic obstructive pulmonary disease：current burden and future projections.Eur Respir J，2006，27(2)：397-412.

20.Mannino DM，Higuchi K，Yu TC，et al.Economic Burden of COPD in the Presence of Comorbidities.Chest，2015，148(1)：138-150.

21.Jensen HH，Godtfredsen NS，Lange P，et al.Potential misclassification of causes of death from COPD.Eur Respir J，2006，28(4)：781-785.

22.Hoyert DL，Xu J.Deaths：preliminary data for 2011.Natl Vital Stat Rep，2012，61(6)：1-51.

23.Oberoi S，Barchowsky A，Wu F.The global burden of disease for skin，lung，and bladder cancer caused by arsenic in food.Cancer Epidemiol Biomarkers Prev，2014，23(7)：1187-1194.

24.Menzin J，Boulanger L，Marton J，et al.The economic burden of chronic obstructive pulmonary disease(COPD)in a U.S.Medicare population.Respir Med，2008，102(9)：1248-1256.

25.Chiang CH.Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.Respirology，2008，13(5)：689-694.

26.Guarascio AJ，Ray SM，Finch CK，et al.The clinical and economic burden of chronic obstructive pulmonary disease in the USA.Clinicoecon Outcomes Res，2013，5：235-245.

27.Sin DD，Stafinski T，Ng YC，et al.The impact of chronic obstructive pulmonary diseaseon work loss in the United States.Am J Respir Crit Care Med，2002，165(5)：704-707.

28.Murray CJ，Barber RM，Foreman KJ，et al.Global，regional，and national disability-adjusted life years(DALYs)for 306 diseases and injuries and healthy life expectancy(HALE)for 188 countries，1990-2013：quantifying the epidemiological transition.Lancet，2015，386(10009)：2145-2191.

29.McCloskey SC，Patel BD，Hinchliffe SJ，etal.Siblings of patientswith severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction.Am JRespir Crit Care Med，2001，164(8 Pt 1)：1419-1424.

30.Hunninghake GM，Cho MH，TesfaigziY，etal.MMP12，lung function，and COPD in high-risk populations.N Engl JMed，2009，361(27)：2599-2608.

31.Mercado N，Ito K，Barnes PJ.Accelerated ageing of the lung in COPD：new concepts.Thorax，2015，70(5)：482-489.

32.Menezes AM，Landis SH，Han MK，et al.Continuing to confront COPD International Surveys：comparison of patientand physician perceptions about COPD risk and management.Int J Chron Obstruct Pulmon Dis，2015，10：159-172.

33.Tam A，Churg A，Wright JL，et al.Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med，2016，193(8)：825-834.

34.Lawlor DA，Ebrahim S，Davey SG.Association of birth weightwith adult lung function：findings from the British Women′s Heart and Health Study and ameta-analysis.Thorax，2005，60(10)：851-858.

35.Wipfli H，Samet JM.Global economic and health benefits of tobacco control：part 1.Clin Pharmacol Ther，2009，86(3)：263-271.

36.Kohansal R，Martinez-Camblor P，AgustíA，et al.The natural history of chronic airflow obstruction revisited：an analysis of the Framingham offspring cohort.Am JRespir Crit Care Med，2009，180(1)：3-10.

37.Hagstad S，Bjerg A，Ekerljung L，et al.Passive smoking exposure is associated with increased risk of COPD in never smokers.Chest，2014，145(6)：1298-1304.

38.Hollams EM，de Klerk NH，Holt PG，et al.Persistent effects ofmaternal smoking during pregnancy on lung function and asthma in adolescents.Am JRespir Crit Care Med，2014，189(4)：401-407.

39.Tager IB，Ngo L，Hanrahan JP.Maternal smoking during pregnancy.Effects on lung function during the first 18 months of life.Am JRespir Crit Care Med，1995，152(3)：977-983.

40.Paulin LM，Diette GB，Blanc PD，et al.Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med，2015，191(5)：557-565.

41.Marchetti N，Garshick E，Kinney GL，et al.Association between occupational exposure and lung function，respiratory symptoms，and highresolution computed tomography imaging in COPDGene.Am JRespir Crit Care Med，2014，190(7)：756-762.

42.周玉民，王辰，姚婉贞，等.职业接触粉尘和烟雾对慢性阻塞性肺疾病及呼吸道症状的影响.中国呼吸与危重监护杂志，2009，8(1)：6-11.

43.Balmes J，Becklake M，Blanc P，et al.American Thoracic Society Statement：Occupational contribution to the burden of airway disease.Am JRespir Crit Care Med，2003，167(5)：787-797.

44.Gan WQ，FitzGerald JM，Carlsten C，et al.Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality.Am JRespir Crit Care Med，2013，187(7)：721-727.

45.Eisner MD，Anthonisen N，Coultas D，et al.An official American Thoracic Society public policy statement：Novel risk factors and the global burden of chronic obstructive pulmonary disease.Am JRespir Crit Care Med，2010，182(5)：693-718.

46.Gauderman WJ，Avol E，Gilliland F，et al.The effect of air pollution on lung development from 10 to18 years of age.N Engl JMed，2004，351(11)：1057-1067.

47.Beran D，Zar HJ，Perrin C，et al.Burden of asthma and chronic obstructive pulmonary disease and access to essentialmedicines in lowincome and middle-income countries.Lancet Respir Med，2015，3(2)：159-170.

48.Gershon AS，Warner L，Cascagnette P，et al.Lifetime risk of developing chronic obstructive pulmonary disease：a longitudinal population study.Lancet，2011，378(9795)：991-996.

49.Prescott E，Lange P，Vestbo J.Socioeconomic status，lung function and admission to hospital for COPD：results from the Copenhagen City Heart Study.Eur Respir J，1999，13(5)：1109-1114.

50.李小芡，胡志，李守田，等.安徽农村不同居住环境对慢阻肺患病率的影响.中国农村卫生事业管理，2002，22(4)：46-48.

51.Silva GE，Sherrill DL，Guerra S，et al.Asthma as a risk factor for COPD in a longitudinal study.Chest，2004，126(1)：59-65.

52.Vonk JM，Jongepier H，Panhuysen CI，et al，Postma DS.Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patientswith asthma after 26 years of follow up.Thorax，2003，58(4)：322-327.

53.McGeachie MJ，Yates KP，Zhou X，et al.Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma.N Engl J Med，2016，374(19)：1842-1852.

54.Fabbri LM，Romagnoli M，Corbetta L，et al.Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease.Am J Respir Crit Care Med，2003，167(3)：418-424.

55.To T，Zhu J，Larsen K，et al.Progression from Asthma to Chronic Obstructive Pulmonary Disease.Is Air Pollution a Risk Factor.Am J Respir Crit Care Med，2016，194(4)：429-438.

56.Tashkin DP，Altose MD，Connett JE，et al.Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease.The Lung Health Study Research Group.Am JRespir Crit Care Med，1996，153(6 Pt1)：1802-1811.

57.Kim V，Han MK，Vance GB，et al.The chronic bronchitic phenotype of COPD：an analysis of the COPD Gene Study.Chest，2011，140(3)：626-633.

58.de Marco R，Accordini S，Marcon A，et al.Risk factors for chronic obstructive pulmonary disease in a European cohortof young adults.Am JRespir Crit Care Med，2011，183(7)：891-897.

59.慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重诊治中国专家共识(草案).中国呼吸与危重监护杂志，2013，12(6)：541-551.

60.Drummond MB，Kirk GD.HIV-associated obstructive lung diseases：insights and implications for the clinician.Lancet Respir Med，2014，2(7)：583-592.

61.Barnes PJ.Inflammatorymechanisms in patientswith chronic obstructive pulmonary disease.J Allergy Clin Immunol，2016，138(1)：16-27.

62.Sze MA，Dimitriu PA，SuzukiM，et al.Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med，2015，192(4)：438-445.

63.Lee SH，Goswami S，Grudo A，et al.Antielastin autoimmunity in tobacco smoking-induced emphysema.Nat Med，2007，13(5)：567-569.

64.Retraction：Decline in NRF2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator，DJ-1;Heightened Endoplasmic Reticulum Stress in the Lungs of Patients with Chronic Obstructive Pulmonary Disease：The Role of Nrf2-Regulated Proteasomal Activity.Am J Respir Crit Care Med，2016，193(3)：344.

65.Johnson SR.Untangling the proteaseweb in COPD：metalloproteinases in the silent zone.Thorax，2016，71(2)：105-106.

66.Barnes PJ.Cellular and molecular mechanisms of chronic obstructive pulmonary disease.Clin Chest Med，2014，35(1)：71-86.

67.Churg A，Tai H，Coulthard T，et al.Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall.Am JRespir Crit Care Med，2006，174(12)：1327-1334.

68.Rennard SI，Kv W.Rationale and emerging approaches for targeting lung repair and regeneration in the treatment of chronic obstructive pulmonary disease.Proc Am Thorac Soc，2011，8(4)：368-375.

69.Barnes PJ.Immunology of asthma and chronic obstructive pulmonary disease.Nat Rev Immunol，2008，8(3)：183-192.

70.McDonough JE，Yuan R，Suzuki M，et al.Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.N Engl J Med，2011，365(17)：1567-1575.

71.Elbehairy AF，Ciavaglia CE，Webb KA，et al.Pulmonary Gas Exchange Abnormalities in Mild Chronic Obstructive Pulmonary Disease.Implications for Dyspnea and Exercise Intolerance.Am JRespir Crit Care Med，2015，191(12)：1384-1394.

72.Casaburi R，Maltais F，Porszasz J，et al.Effects of tiotropium on hyperinflation and treadmillexercise tolerance inmild tomoderate chronic obstructive pulmonary disease.Ann Am Thorac Soc，2014，11(9)：1351-1361.

73.Rodríguez-Roisin R，Drakulovic M，Rodríguez DA，et al.Ventilationperfusion imbalance and chronic obstructive pulmonary disease staging severity.JAppl Physiol(1985)，2009，106(6)：1902-1908.

74.Burgel PR，Nadel JA.Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases.Eur Respir J，2008，32(4)：1068-1081.

75.Peinado VI,Pizarro S,.Pulmonary vascular involvement in COPD.Chest,2008,134(4):808-814.

76.Wells JM,Washko GR,Han MK,et al.Pulmonary arterial enlargement and acute exacerbations of COPD.N Engl J Med,2012,367(10):913-921.